Brachytherapy in an advanced stage of pancreatic cancer - a case report by Kycler, W. et al.
Introduction
Every year about 3200 new cases of pancreatic cancer
are registered in Poland. A considerable percentage of pa-
tients (85-90%) commence treatment in advanced sta-
ges of disease [1] and relative five-year survivals after ra-
dical surgical resection reach about 10 %. [2]. According
to the literature data patients with unresectable pancreatic
adenocarcinoma die within 6 months after the operation
[2,3].
Radical surgical resection is the treatment of choice.
Unfortunately, radical treatment cannot be applied to
a majority of patients as they are already in advanced
stages of the disease. For this very reason treatment
options for pancreatic cancer remain limited. Chemo-ra-
diotherapy, palliative surgery and brachytherapy are con-
sidered as testable treatment concepts for locally advan-
ced pancreatic cancer [3-6].
Unresectable pancreatic cancers are very difficult to
treat with external beam therapy alone, due to the proxi-
mity of adjacent normal organs and the high doses requ-
ired to effectively irradiate these neoplasms [7].
Brachytherapy is one of the most efficient palliative
methods of treatment. It diminishes pain, reduces tumor-
-mass effect and slows the growth of the tumor.
Indications for HDR brachytherapy are:
– palliative treatment (in a majority of cases) [4, 7],
– presurgical treatment (to induce regression of locally
advanced cancers) [5],
– postsurgical treatment with catheters implanted into
the residual mass of the tumour [2, 9],
– radical treatment (in some individual cases) combi-
ned with external beam radiotherapy and/or chemothe-
rapy [6-9].
Perioperative permanent implantation of 125I or
123Pd is being investigated as a method applied to unre-
sectable tumors at the time of laparotomy [10-12]. By-
pass procedures often accompany implantation and exter-
nal beam radiation usually follows. In case of patients
with unresectable tumors the disease has to be confined to
the pancreas with the tumor less than 5-6 cm in size. Pe-
rioperative HDR irradiation of pancreatic cancers thro-
ugh plastic tube implantations is also being explored as
a means of increasing the dose to an unresectable lesion
[6, 13].
The efficacy of brachytherapy, as compared with the
efficacy of external beam alone, may be attributed to the
possibility of delivering a higher concentrated radiation
dose to the tissues with more precision, thus improving lo-
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cal control, provided that the tissue is clinically delimita-
ble and accessible. At the same time, the surrounding
healthy tissues are spared. In contrast to external-beam ir-
radiation, brachytherapy is invasive as it requires the in-
sertion of site-specific applicators under sedation or ana-
esthesia.
We present a case of a patient with locally advan-
ced pancreatic cancer who had been treated with intersti-
tial brachytherapy at the Greatpoland Cancer Centre,
Poznaƒ.
Case report
A 79- year old man was admitted with an 8-month histo-
ry of recurrent varices haemorrhoidales inflammation.
The patient suffered from occasional presence of myxo-
matous stools. He had no serious illness before that.
He was in good general condition, free of symptoms
suggesting neoplastic disease. Abdominal ultrasound (per-
formed 6 months before treatment), colonoscopy and do-
uble contrast method colon exam were normal. Recto-
scopy revealed varices haemorrhoidales. The patient was
qualified for surgery due to recurrent varices haemorrho-
idales inflammation.
In March 2000 he was admitted to the Greatpoland
Cancer Center, 2nd Department of Oncological Surgery in
Poznaƒ. Presurgical exams were ordered. The abdomi-
nal ultrasound showed a solid 5 cm tumour in the head of
pancreas. Hematological and biochemical tests, chest X-
-ray and double contrast colon exam were normal. There
was no evidence of extrapancreatic spread of the dise-
ase. Cytological diagnosis by fine needle aspiration under
CT control was performed, providing a diagnosis of cellu-
lae carcinomatosae – adenocarcinoma.
The patient was qualified for surgery. A 5 cm-diame-
ter tumor was discovered in the head of the pancreas du-
ring laparotomy. There was no evidence of metastatic di-
sease in the abdomen. On intraoperative estimation the
tumor was pronounced unresectable.
During surgery three parallel "blind-end" intratissu-
al catheters were implanted into the tumor mass at 1 cm
distances.
Brachytherapy was started on the second day after
the operation. IBU (Integrated Brachytherapy Unit)
check photos were made and imaging information was
transferred to the treatment planning computer via an
information network. The target volume contained the
tumor mass with a 1 cm margin (85% isodose of refe-
rence dose). PLATO planning system was used.
For HDR brachytherapy a microselectron HDR unit
was used, with Iridium 192 as the radioactive source –
10 Ci activity.
The patient received 10 fractions of 3 Gy daily, total
dose reaching 30 Gy. Treatment tolerance was good and
no complications were observed. Recovery was uncompli-
cated and the patient was discharged on the 14-th day
after surgery.
From then on the patient remained under the care of
a family doctor and did not report to our hospital. 14
months after surgery and brachytherapy the patient obse-
rved disturbances reported as alternate diarrhoea and
constipation.
Abdominal ultrasound revealed liver with steatosis –
solid, heterogenous, without disintegration features with
non-extended bile ducts and a tumor of 4-5 cm in dia-
meter localized in the head of pancreas. Intra-abdominal-
ly, on the right hand side the colon (caecum) wall was
thickened (reaching 18 mm) and stiffened over a distance
of some 6 cm (Tu coeci). The family doctor advised pallia-
tive treatment.
Four months later, in October 2001, the patient re-
ported to the Greatpoland Cancer Center with the above-
-mentioned complaints.
The abdominal ultrasound showed hyper- and hy-
poechogenic, meta-characteristic focuses in the right lobe
of the liver. Laboratory test revealed an increased CEA –
500 ng/mL (normal value below 3,0 ng/mL).
Because of subileus, the patient was immediately
admitted and qualified for laparotomy (10.2001). A mova-
ble tumor was discovered in the caecum during laparoto-
my. Separate metastatic tumours were found in the liver.
The tumour originating from the head of the pancreas
infiltrated the back wall of the duodenum. Right hemico-
lectomy was performed.
The operation was palliative in its character. The
post operative course was uncomplicated and the patient
was discharged on day 18 after surgery.
The pathology report revealed adenocarcinoma tu-
bulopapillare (G2), infiltratio carcinomatosa profunda
tunicae muscularis propriae et serosae coli et telae adipo-
sae pericolicae, lymphonodulitis reactiva No XV, G2, Du-
kes B, Astler Coller B2, pT3. The tumour infiltrated over
the entire wall of the small intestine.
The last medical examination was performed 3 mon-
ths after surgery: the patient was generally in quite good
condition, able to move, free of pain and with the wo-
und completely healed.
The entire observation time from pancreatic cancer
diagnosis reached 24 months.
Discussion
Non-specific symptoms of pancreatic cancer delay the
diagnosis. The conventional triade – epigastric pain, we-
ight loss and icterus appear in advanced stages of pancre-
atic tumours. Usually the first symptom is a perceptible
abdominal mass in the epigastrium or a tumor accidental-
ly detected during ultrasonography. Other symptoms,
such as non-specific pains in the upper abdomen, loss of
appetite, diabetes and psychological disturbances are
obviously non- characteristic. In a few cases one may ad-
ditionally observe symptoms connected with hyperten-
sion in the inferior caval vein.
Locally advanced cancer estimated on surgery ren-
ders radical excision impossible. Brachytherapy provides
promising results – tumor progression may be stopped.
The patient, whose case we report, didn't report any
pain. Also no alimentary tract dysfunction nor icterus
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were reported. At the time when the patient reported
with symptoms of a second cancer his quality of life as
a pancreatic cancer survivor was good [14]. The survival
expectancy in case of advanced, unresected pancreatic
cancer (clinical stage III and IV) is, approximately, six
months [3, 10].
Different authors report the advantages of palliative
treatment with HDR brachytherapy. The satisfactory re-
sults of this method have widened the application of this
method. Neoadjuvant therapy has the potential to induce
regression of locally advanced cancers and render them
resectable.
Wanebo and al. [5] used preoperative chemoradio-
therapy as a testable treatment concept for locally ad-
vanced pancreatic cancer. Fourteen surgically staged pa-
tients with locally advanced pancreatic cancer, disqualified
from radical surgery, were treated by preoperative chemo-
therapy. After treatment, they were qualified for re-explo-
ration and resection. 81 % (9 patients) underwent pancre-
atic resection including standard Whipple resection, resec-
tion of body and neck and extended resection. The
histopathology examination indicated complete patholo-
gic response in two patients, one patient had no residual
cancer, another (who had iridium 192 brachytherapy)
had normal core biopsies of the pancreatic head, and five
others had incomplete pathologic response. All 9 patients
achieved 5-year survival.
Pfreungner and al. [3] have presented clinical re-
ports of 19 patients with unresectable pancreatic cancer.
9 women and 10 men underwent interstitial brachythera-
py. Distribution according to UICC stages has shown 4,10
and 5 patients in stages II to IV, respectively. A total do-
se of 10 to 34 Gy to the reference isodose was delivered
(single dose – 1.88 to 5 Gy). Brachytherapy was followed
by external beam therapy, delivering an additional dose of
40 to 58 Gy. Median survival time was 6 months, local
control rate was 70%. Brachytherapy treatment was well
tolerated, severe acute side effects were not observed.
Authors concluded, that 192Iridium brachytherapy is com-
parable to IORT (intraoperative radiotherapy) or seed
implantation.
These good results of brachytherapy are a sufficient
cause for the further development of this method. Intra-
tumoral infusional brachytherapy using macroaggrega-
ted human albumin in combination with radioactive chro-
mic phosphate (32P) extends the possibility to admini-
ster brachytherapy to tumors, the location of which makes
it impossible to implant catheters [2, 9].
In the presented case the main clinical problem aro-
se from the fact that the patient with a non-resectable
pancreatic cancer developed a second malignancy.
During the four months after the diagnosis of the
second malignancy the patient was not referred for surge-
ry. In June 2001 abdominal ultrasound provided symp-
toms of a caecum tumor with evidence of healthy liver pa-
renchyma. On admission to the surgery department the
abdominal ultrasound revealed a metastatic liver. The
clinical advance of caecum cancer rendered radical surgi-
cal treatment impossible and the patient’s condition dete-
riorated.
During the 24 months after the onset of pancreatic
cancer treatment we achieved good results of palliative
treatment. We didn't observe any side effects after brachy-
therapy. The development of the second cancer and post-
poned surgical treatment caused progression of the ca-
ecum cancer which, in due time, metastasied.
We believe that combining surgery and brachythera-
py in the treatment of locally advanced pancreatic cancer
is an efficient and safe palliative treatment method.
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